media – Page 89 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Why are small hearing aids stuck in the neck?

Although hearing aids do not look complicated, their research and development is not simple at all. Digital hearing aids use nonlinear amplification to compress and limit loud sounds and amplify small sounds, making the processed sounds comfortable and clear. To achieve this process, digital hearing aids use DSP digital signal processing chips, use digital technology to segment sound signals, and integrate adaptive noise reduction, acoustic feedback suppression, equalizers and other algorithms that can improve the performance of hearing aids, making the sound of hearing aids clearer and more capable of suppressing whistling. Therefore, in the transformation process of digital hearing aids, the core technology threshold is indeed mainly concentrated in two key areas: First, digital hearing aid chips. These chips are the heart of hearing aids, responsible for processing sound signal amplification, filtering, digital processing, etc. They need to have the characteristics of high speed, low power consumption and high ...
- Source: drugdu
- 97
- September 5, 2024
Pharmintech

Organiser: Packaging Machinery Manufacturers Institute (PMMI), USA Time: May 3 – 6, 2025 Address: Piazza della Costituzione, 540128 Bologna, Italy Exhibition hall: Bologna Fiere Product range: Pharmaceutical Processing & Packaging (Packaging Machinery; Liquid Processing Equipment; Labeling, Coding, Recording, Tracking, and RFID Systems) Pharmaceutical Industry Containers & Materials for Primary to Tertiary Packaging Raw Materials, Packaging, & Containers (Packaging Containers & Materials; Equipment; Ancillary Packaging Equipment & Materials; Packaging Components, etc.) Ancillary Equipment & Packaging Materials Packaging & Packaging Accessories Raw Materials for Pharmaceuticals, Personal Care Products, & Nutrition Industries Infrastructure, Factories, Logistics, etc. About Pharmintech： Pharmintech Bologna, held in Bologna, Italy, is one of the most influential pharmaceutical packaging exhibitions in Italy and across Europe. It offers professionals in the pharmaceutical and allied pharmaceutical industries a close-up introduction to the world’s latest solutions in processes, packaging machinery, raw materials, infrastructure, factories, logistics, packaging materials, containers, and services.
- Source: drugdu
- 301
- September 5, 2024
The Low Point of Performance Due to Centralized Procurement Has Passed, and Tonghua Dongbao Ushered in a Stable Development Period

On the evening of August 30, Tonghua Dongbao (600867.SH) released its 2024 semi-annual report, during the report period, the company achieved operating income of about 740 million yuan, a year-on-year decrease of 45.84%; net profit attributable to shareholders of listed companies of about -230 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of about -0.13 billion yuan. Industry analysts believe that the reason why Tonghua Dongbao fell into a loss, stemming from the biggest cyclical factors – insulin special centralized procurement. Similar to the first centralized procurement, the results of this year’s renewal have not been reflected in the performance for the time being. The main reason for the company’s first-half performance fluctuations is a one-time dealer to make up the difference, which was also the case in the last centralized procurement, fell to a low point in the second quarter, the ...
- Source: drugdu
- 120
- September 5, 2024
Lancet reports that semaglutide has the potential to be used in heart failure patients

According to analysis, semaglutide reduced the composite risk of cardiovascular (CV) death or worsening heart failure (HF) events by 31%, with incidence rates of 5.4% in the semaglutide group and 7.5% in the placebo group (HR 0.69; 95% CI 0.53-0.89; P=0.0045). semaglutide also reduced the risk of HF worsening by 41% (2.8% vs. placebo 4.7%; HR 0.59 (95% CI 0.41-0.82), p=0.0019). Simeglutide had no significant effect on the incidence of CV mortality (3.1% in the Simeglutide group and 3.7% in the placebo group). Hr 0.82 (95% CI 0.57-1.16), p=0.25) The statistical analysis did not adjust for multiplicity, and the hazard ratio should not be used to infer definitive treatment efficacy. In the United States, semaglutide is not approved for use in heart failure. This study is a summary and post hoc participant level analysis of 3743 patients with a history of HFpEF from four randomized trials, aimed at examining the ...
- Source: drugdu
- 175
- September 4, 2024
AI imaging company Yinghe Yimai announces completion of angel round financing

Today (September 2nd), Shanghai Yinghe Yimai Intelligent Technology Co., Ltd. (hereinafter referred to as “Yinghe Yimai”) announced the completion of an angel round financing of tens of millions of yuan, led by CICC Capital, marking a solid step forward for Yinghe Yimai in promoting the intelligentization of medical imaging. Multiple core products, focusing on intelligent medical imaging Yinghe Medical Pulse was founded in 2020 and is a continuous innovator in the field of medical imaging artificial intelligence based on its newly developed MIIA base model. In response to the current situation where medical imaging AI products are generally single disease, fragmented, and homogeneous, and cannot meet the actual needs of image reading work, Yinghe Medical Pulse is an emerging technology enterprise focused on medical imaging AI integration and research and development. It is committed to providing medical imaging auxiliary tools based on AI and statistical methods, as well as medical ...
- Source: drugdu
- 140
- September 4, 2024
How to select T cell targeted antibodies in the strategy of antibody conjugated LNP (Ab LNP) for mRNA CAR-T therapy

Biological Products Circle September 3, 2024 09:20 Hubei The following article is from the Engineering Bacteria Planet, written by the author Yaojun, who has doubled in numberCurrently, the FDA has approved multiple chimeric antigen receptor (CAR) – T-cell therapies for cancer immunotherapy. However, the production technology based on viral vectors and in vitro cell culture has led to high production costs and potential long-term side effects. With the development of mRNA and lipid nanoparticle (LNP) technology, the idea of in vivo delivery of CARs based on LNP, a non viral vector, is expected to be realized. The primary challenge faced by mRNA LNP mediated CAR-T therapy due to its liver tropism is how to achieve mRNA T cell targeting The use of antibody modified LNP (also known as antibody conjugated LNP, Ab LNP) is an effective solution. So, what are the markers on the surface of T cells and how ...
- Source: drugdu
- 145
- September 4, 2024
Will Novo Nordisk’s Wegovy follow up with the price reduction of over 50% for Eli Lilly’s Zepbound?

MU Biotech Circle Recently, Eli Lilly announced plans to directly sell single dose vials of its weight loss drug Zepbound (tirzepatide) to consumers. The new prices for 2.5mg and 5.0mg doses are $99.75/vial and $137.25/vial, respectively, with corresponding monthly costs of $399 and $549, respectively, with a price reduction of over 50%. Novo Nordisk may adopt a similar strategy towards its Wegovy, with specific details to be revealed by its CEO during a Senate Health Committee hearing on September 24th. Analysts have responded positively to Eli Lilly’s move to lower Zepbound prices and offer the drug through its new self funded pharmacy component on its direct to consumer platform LillyDirect (launched in January this year). Joon Lee, an analyst at Truist Securities, believes that given the high demand for patients willing to purchase at their own expense, there is no reason why other GLP-1 manufacturers should not adopt similar strategies. ...
- Source: drugdu
- 109
- September 4, 2024
Jimin Health aims at the new biomedical technology track

As one of the first hospitals to enter the Boao Lecheng International Medical Tourism Zone in Hainan, the Boao International Hospital of Jimin Health, relying on the policy advantage of “early and pilot implementation” of the zone, has focused its R&D efforts on two major R&D pipelines of adipose-derived mesenchymal stem cells and dendritic cells in the field of cellular therapeutic drugs. Tian Yunfei, director and president of Jimin Health, recently said in an interview with China Securities Journal, “Based on the long-term optimism for the development prospect of cell therapy drugs, Jimin Health will focus on the research and development of Boao International Hospital’s cell therapy drug pipeline in the future.” Joining hands with stem cell experts JiminHealth’s 2024 semi-annual report disclosed the appointment of Jonathan Robert Lakey as the chief scientist of the International Regenerative Medicine Research Center of Boao International Hospital, a controlling subsidiary, and that the ...
- Source: drugdu
- 116
- September 4, 2024
The “scale trap” of chain drug stores

1. The more you open, the more you lose In the past few years, drug stores have sprung up all over the country. Whether it is a first-tier city or a small county town, you can see a drug store almost every 50 meters, and there are at least three drug stores at the entrance of a community. The “proliferation” of drug stores has exceeded many people’s imagination. By the end of 2023, there will be nearly 700,000 retail pharmacies in my country, which is more than 100,000 more than the milk tea shops that are everywhere on the streets. In 2012, there were only 440,000 drug stores in my country. In 12 years, the number of drug stores has increased by nearly 50%. Although milk tea shops and snack shops have sprung up in the streets and alleys, they are nothing compared to the expansion speed of chain drug ...
- Source: drugdu
- 69
- September 4, 2024
Under the great changes! Thinking about the development strategy of pharmaceutical companies

1. Cycles exist objectively, but they are not impossible to cross In recent years, the concept we first used was the “new normal”. The term “new normal” actually lowers social expectations in advance. Later, many experts introduced the concept of “cycle” with the intention of incorporating the current economic situation into a historical cycle. Admittedly, economic development has cycles, and even the spread of viruses has cycles. However, “today’s economic and social conditions should mainly be the result of active choices made by decision-makers. Cyclical factors have an effect but are not decisive, or the adjustment of development direction “encounters” cyclical factors”-excerpted from Du Chen’s “Our Times and Us in the Times”. 2. The current difficulties may only be the initial stage The “new cycle” has just begun, and we must be prepared for long-term hard work. Combining data from the National Bureau of Statistics, Minnet, IQVIA, etc., the average ...
- Source: drugdu
- 64
- September 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.